Mesoblast Limited (MESO): Price and Financial Metrics


Mesoblast Limited (MESO): $2.88

0.28 (+10.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MESO POWR Grades


  • MESO scores best on the Growth dimension, with a Growth rank ahead of 86.5% of US stocks.
  • MESO's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • MESO's current lowest rank is in the Quality metric (where it is better than 1.86% of US stocks).

MESO Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MESO is 0.02 -- better than merely 7.73% of US stocks.
  • Of note is the ratio of Mesoblast Ltd's sales and general administrative expense to its total operating expenses; merely 12.21% of US stocks have a lower such ratio.
  • MESO's price/sales ratio is 56.64; that's higher than the P/S ratio of 96.47% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Mesoblast Ltd, a group of peers worth examining would be MUX, GTEC, ESLT, RBBN, and ALV.
  • MESO's SEC filings can be seen here. And to visit Mesoblast Ltd's official web site, go to www.mesoblast.com.

MESO Valuation Summary

  • MESO's price/earnings ratio is -8.6; this is 123.56% lower than that of the median Healthcare stock.
  • Over the past 71 months, MESO's EV/EBIT ratio has gone down 3.7.
  • Over the past 71 months, MESO's EV/EBIT ratio has gone down 3.7.

Below are key valuation metrics over time for MESO.

Stock Date P/S P/B P/E EV/EBIT
MESO 2021-08-31 113.6 1.5 -8.6 -9.2
MESO 2021-08-30 139.5 1.4 -7.9 -8.0
MESO 2021-08-27 140.8 1.4 -7.9 -8.0
MESO 2021-08-26 139.8 1.4 -7.9 -8.0
MESO 2021-08-25 141.0 1.4 -7.9 -8.0
MESO 2021-08-24 138.1 1.4 -7.8 -7.9

MESO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MESO has a Quality Grade of F, ranking ahead of 0.82% of graded US stocks.
  • MESO's asset turnover comes in at 0.01 -- ranking 391st of 680 Pharmaceutical Products stocks.
  • RGEN, STAB, and OTLK are the stocks whose asset turnover ratios are most correlated with MESO.

The table below shows MESO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.010 1 -2.497
2021-03-31 0.009 1 -2.975
2020-12-31 0.024 1 -2.483
2020-09-30 0.023 1 -2.357
2020-06-30 0.047 1 -1.700
2020-06-30 0.047 1 -1.700

MESO Stock Price Chart Interactive Chart >

Price chart for MESO

MESO Price/Volume Stats

Current price $2.88 52-week high $7.88
Prev. close $2.60 52-week low $2.14
Day low $2.71 Volume 140,300
Day high $2.93 Avg. volume 75,129
50-day MA $3.15 Dividend yield N/A
200-day MA $4.56 Market Cap 374.66M

Mesoblast Limited (MESO) Company Bio


Mesoblast Ltd. has established a diverse portfolio of product candidates based on its proprietary allogeneic, off-the-shelf mesenchymal lineage cell-based technology, with multiple active Phase 3 clinical programs. Mesoblast's lead product candidates target major diseases with significant unmet medical needs despite existing therapies. These include chronic heart failure, chronic low back pain due to degenerative disc disease, and immune-mediated conditions such as acute graft versus host disease and biologic refractory rheumatoid arthritis. The company is based in Melbourne, Australia.


MESO Latest News Stream


Event/Time News Detail
Loading, please wait...

MESO Latest Social Stream


Loading social stream, please wait...

View Full MESO Social Stream

Latest MESO News From Around the Web

Below are the latest news stories about Mesoblast Ltd that investors may wish to consider to help them evaluate MESO as an investment opportunity.

Operational Highlights and Financial Results for the Period Ended December 31, 2021

Mesoblast Prepares for Resubmission of Biologics License Application Mesoblast Prepares for Resubmission of Biologics License Application

GlobeNewswire | February 24, 2022

Mesoblast GAAP EPS of -$4.00, revenue of $2.38M

Mesoblast press release (MEOBF): Q2 GAAP EPS of -$4.00.Revenue of $2.38M (+6.3% Y/Y).

Seeking Alpha | February 24, 2022

Mesoblast Corporate Update and Financial Results Webcast

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the second quarter ended December 31, 2021. The webcast will begin at 5.00pm EST, Thursday, February 24; 9.00am AEDT, Friday, February 25, 2022. It can be accessed via: https://webcast.openbriefing.com/8499/ The archived webcast will be available on the Invest

Yahoo | February 24, 2022

Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohn''s Colitis After Direct Injection of Remestemcel-L by Colonoscopy

NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO , ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced positive results from an interim analysis of the first patient cohort in the randomized, controlled study of remestemcel-L by direct endoscopic delivery to areas of inflammation in patients with medically refractory ulcerative colitis or Crohn''s colitis. A single local delivery of remestemcel-L by colonoscopy resulted in rapid mucosal healing and disease remission in these refractory patients at high risk of progression to surgery. The results of the first cohort of patients were presented at the 17 th Congress of European Crohn''s and Colitis Organisation (ECCO), February 16-19, by the trial''s lead investiga...

Benzinga | February 20, 2022

Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohn’s Colitis After Direct Injection of Remestemcel-L by Colonoscopy

Results of First Patient Cohort from Randomized Controlled Study Presented at Congress of European Crohn’s and Colitis Organisation (ECCO)NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced positive results from an interim analysis of the first patient cohort in the randomized, controlled study of remestemcel-L by direct endoscopic delivery to areas of inflammation in patie

Yahoo | February 20, 2022

Read More 'MESO' Stories Here

MESO Price Returns

1-mo -5.88%
3-mo -33.79%
6-mo -38.33%
1-year -61.85%
3-year -47.73%
5-year -64.13%
YTD -40.00%
2021 -43.46%
2020 15.20%
2019 78.88%
2018 -29.45%
2017 9.16%

Continue Researching MESO

Here are a few links from around the web to help you further your research on Mesoblast Ltd's stock as an investment opportunity:

Mesoblast Ltd (MESO) Stock Price | Nasdaq
Mesoblast Ltd (MESO) Stock Quote, History and News - Yahoo Finance
Mesoblast Ltd (MESO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.539 seconds.